Cerevance reports positive Phase 3 Arise results for once-daily solengepras in Parkinson's
Reuters says Cerevance's Phase 3 Arise trial found once-daily oral solengepras met the primary endpoint: reducing daily off time by 0.61 hours vs placebo at week 12, and showed motor and non-motor benefits; adverse-event discontinuation was 3.5%, same as placebo.